Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SSR128129E (SSR) 是一种变构和口服活性 FGFR1 抑制剂 (IC50:1.9 μM),但不影响其他相关的 RTK。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 298 | 现货 | ||
5 mg | ¥ 482 | 现货 | ||
10 mg | ¥ 776 | 现货 | ||
25 mg | ¥ 1,390 | 现货 | ||
50 mg | ¥ 2,470 | 现货 | ||
100 mg | ¥ 3,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 795 | 现货 |
产品描述 | SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting other related RTKs. |
靶点活性 | FGFR1:1.9 μM |
体外活性 | 在各种小鼠肿瘤模型中,SSR128129E(30 mg/kg,p.o.)可同时抑制原发性肿瘤的增殖和转移.在患有关节炎的小鼠中,SSR128129E(30 mg/kg,p.o.)抑制了炎症、血管生成和骨吸收,并缓解了临床症状.此外,SSR128129E对抗血管内皮细胞生长因子受体2顽固型肿瘤模型和敏感株的增殖有抑制作用,并增加抗血管内皮细胞生长因子受体2的抗肿瘤活性. |
体内活性 | 由于变构机制,SSR128129E在细胞实验中具有更强的活性。SSR128129剂量依赖性抑制FGF2-诱导的EC增殖和迁移(IC50:31/15.2 nM)。作为多靶点成纤维细胞生长因子受体抑制剂,SSR128129E抑制了FGFR1-4介导的反应,从而使多种细胞系的增殖和/或迁移被阻断,比如mPanc02,HEK-hFGFR2WT,PAE-hFGFR1,hB9-myeloma和人脐静脉内皮细胞株。 |
激酶实验 | Scintillation Proximity Assay, 125I-FGF-2 Binding: SPA protein A beads are supplied as a suspension in PBS at 20 mg/mL, then diluted with binding buffer (KCl, 400 mg/L; MgSO4 200 mg/L; NaCl 6.4 g/L; NaHCO3 3.7 g/L; NaH2PO4 0.141 mg/mL; bis Tris Propane 11.292 g/L; Glucose 4.5 g/L; Gelatin 0.1 %; pH 7.0) at 10 mg/mL. 125I-FGF-2 radioligand and FGFR-1IIIc? - Fc Chimera are diluted into binding buffer. Binding was performed on 96-well plates coated with 0.1 % gelatin. Total assay volume is 0.1 mL. Binding of 125I-FGF-2 is determined by incubation of SPA beads coated with protein A (0.5 mg/assay) with FGFR-1IIIc? - Fc chimera soluble receptor (5 ng/assay), FGF-2 (20 ng/assay) is used for non-specific binding determinations. |
细胞实验 | Cell proliferation of porcine aortic endothelial (PAE) and tumor cell lines is analyzed on exponentially growing cells that are starved for 16 hours in 0.2 % FBS containing medium and seeded at 4,000 cells/well in 96-well microplates. After exposure to mitogens and/or SSR for 72 hours, cell proliferation is assessed with the use of the CellTiter 96 AQueous One Solution Cell Proliferation Assay according to manufacturer’s instructions. 10 % FBS containing medium is used a positive control. (Only for Reference) |
别名 | SSR |
分子量 | 346.31 |
分子式 | C18H15N2O4·Na |
CAS No. | 848318-25-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 1 mg/mL (2.88 mM)
DMSO: 64 mg/mL (184.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.8876 mL | 14.4379 mL | 28.8759 mL | 72.1897 mL |
DMSO | 5 mM | 0.5775 mL | 2.8876 mL | 5.7752 mL | 14.4379 mL |
10 mM | 0.2888 mL | 1.4438 mL | 2.8876 mL | 7.219 mL | |
20 mM | 0.1444 mL | 0.7219 mL | 1.4438 mL | 3.6095 mL | |
50 mM | 0.0578 mL | 0.2888 mL | 0.5775 mL | 1.4438 mL | |
100 mM | 0.0289 mL | 0.1444 mL | 0.2888 mL | 0.7219 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SSR128129E 848318-25-2 Angiogenesis Tyrosine Kinase/Adaptors FGFR SSR-128129E SSR Fibroblast growth factor receptor Inhibitor inhibit inhibitor